Barclays’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-90,862
| Closed | -$6.16M | – | 7161 |
|
|
2019
Q3 | $6.16M | Buy |
90,862
+56,207
| +162% | +$3.86M | ﹤0.01% | 1670 |
|
|
2019
Q2 | $2.02M | Buy |
34,655
+6,452
| +23% | +$382K | ﹤0.01% | 2905 |
|
|
2019
Q1 | $1.98M | Buy |
28,203
+17,524
| +164% | +$1.3M | ﹤0.01% | 2590 |
|
|
2018
Q4 | $688K | Sell |
10,679
-189
| -2% | -$13.2K | ﹤0.01% | 3501 |
|
|
2018
Q3 | $764K | Buy |
10,868
+8,526
| +364% | +$499K | ﹤0.01% | 3895 |
|
|
2018
Q2 | $118K | Sell |
2,342
-5,757
| -71% | -$228K | ﹤0.01% | 5128 |
|
|
2018
Q1 | $254K | Buy |
8,099
+4,835
| +148% | +$160K | ﹤0.01% | 4623 |
|
|
2017
Q4 | $111K | Buy |
3,264
+2,743
| +526% | +$87.5K | ﹤0.01% | 5169 |
|
|
2017
Q3 | $17K | Sell |
521
-1,661
| -76% | -$52.4K | ﹤0.01% | 5882 |
|
|
2017
Q2 | $71K | Buy |
2,182
+51
| +2% | +$1.61K | ﹤0.01% | 5140 |
|
|
2017
Q1 | $67K | Sell |
2,131
-3,705
| -63% | -$110K | ﹤0.01% | 5164 |
|
|
2016
Q4 | $172K | Buy |
5,836
+4,544
| +352% | +$139K | ﹤0.01% | 4330 |
|
|
2016
Q3 | $38K | Buy |
1,292
+1,265
| +4,685% | +$35.2K | ﹤0.01% | 5143 |
|
|
2016
Q2 | $1K | Sell |
27
-1,157
| -98% | -$30.7K | ﹤0.01% | 6217 |
|
|
2016
Q1 | $28K | Buy |
1,184
+595
| +101% | +$16.3K | ﹤0.01% | 5087 |
|
|
2015
Q4 | $20K | Sell |
589
-8,336
| -93% | -$223K | ﹤0.01% | 5192 |
|
|
2015
Q3 | $187K | Buy |
8,925
+8,513
| +2,066% | +$219K | ﹤0.01% | 4190 |
|
|
2015
Q2 | $11K | Sell |
412
-553
| -57% | -$15.6K | ﹤0.01% | 6056 |
|
|
2015
Q1 | $29K | Sell |
965
-1,285
| -57% | -$40.8K | ﹤0.01% | 5638 |
|
|
2014
Q4 | $69K | Sell |
2,250
-1,325
| -37% | -$43.1K | ﹤0.01% | 5475 |
|
|
2014
Q3 | $101K | Sell |
3,575
-3,334
| -48% | -$93K | ﹤0.01% | 5322 |
|
|
2014
Q2 | $186K | Buy |
6,909
+2,634
| +62% | +$70.1K | ﹤0.01% | 4885 |
|
|
2014
Q1 | $111K | Buy |
4,275
+1,222
| +40% | +$35.1K | ﹤0.01% | 5360 |
|
|
2013
Q4 | $89K | Sell |
3,053
-958
| -24% | -$30.4K | ﹤0.01% | 5735 |
|
|
2013
Q3 | $121K | Sell |
4,011
-3,785
| -49% | -$127K | ﹤0.01% | 5476 |
|
|
2013
Q2 | $247K | Buy |
+7,796
| New | +$256K | ﹤0.01% | 4975 |
|
Barclays's GHDX Position: Q4 2019 in Review
Barclays sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 90,862 shares — an estimated $6.16M sold.
Barclays first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $6.16M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Barclays reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Barclays sold 90,862 Genomic Health, Inc. shares in Q4 2019, an estimated $6.16M.
- Barclays first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Barclays's Genomic Health, Inc. position peaked at $6.16M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.